Medication
Treatments
- Viscosupplementation: Background and Use in OA
- Two New Biologic Agents for Rheumatoid Arthritis: Rituximab (Rituxan) and Abatacept (Orencia)
- Physical Therapy and CAM: An Educational Tool for Enhancing Integration
- Progressive Multifocal Leukoencephalopathy (PML) in Two Lupus Patients Treated with Rituximab (Rituxan): An HSS Rheumatology Perspective
- HSS Physicians Review Literature on the Safety of COX-2 Inhibitors
Related Conditions
- New Concerns Regarding the Use of Bisphosphonates
- Bextra® Withdrawal from the Market - HSS Physicians Reflect on Options for Patients in Pain
- FDA Alert Regarding Lupus Medication: an HSS Rheumatology Perspective
- CPC: Pulmonary Nodules in an Infliximab-Treated Rheumatoid Arthritis Patient
- Progressive Multifocal Leukoencephalopathy (PML) in Two Lupus Patients Treated with Rituximab (Rituxan): An HSS Rheumatology Perspective
- Vaccinations and Rheumatic Disease
Research
- Revealing How Steroids Work
- Case Report of Spontaneous, Nonspinal Fractures in a Multiple Myeloma Patient on Long-term Pamidronate and Zoledronic Acid
- New Biomarker May Show Whether Patients Can Benefit From Costly Biologic Drugs
- Alendronate Inhibits PTH (1-34)-Induced Bone Morphogenetic Protein Expression in MC3T3-E1 Preosteoblastic Cells
- SH3BP2 is a Critical Regulator of Macrophage and Osteoclast Response to M-CSF and RANKL Stimulation
- Contact HSS
- Give to HSS
- Maps and Directions
- Notice of Privacy Practices
- Terms of Use
- Joint Commission Notice
- HSS Staff Login
© Hospital for Special Surgery. 535 East 70th Street, New York, NY 10021
